Hematology News and Research RSS Feed - Hematology News and Research

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.
Wake Forest Baptist Medical Center receives NCORP grant to conduct cancer clinical trials

Wake Forest Baptist Medical Center receives NCORP grant to conduct cancer clinical trials

Wake Forest Baptist Medical Center has received an $18 million, five-year grant from the National Cancer Institute's Community Oncology Research Program to design and conduct community-based, multi-center screening, prevention and control cancer clinical trials. [More]
BloodCenter's Erythroid Chimerism test available to monitor transplanted SCD patients

BloodCenter's Erythroid Chimerism test available to monitor transplanted SCD patients

BloodCenter of Wisconsin's Diagnostic Laboratories today announced the availability of an innovative Erythroid Chimerism test to monitor erythroid lineage chimerism in patients with sickle cell disease (SCD) following allogeneic bone marrow transplantation. [More]
HICCC receives $18 million grant from the National Cancer Institute

HICCC receives $18 million grant from the National Cancer Institute

Outstanding basic research, a growing focus on translating discoveries into treatments, and a dedication to patient care have earned the Herbert Irving Comprehensive Cancer Center (HICCC) of Columbia University Medical Center (CUMC) and NewYork-Presbyterian Hospital an $18 million, five-year Cancer Center Support Grant from the National Cancer Institute (NCI). [More]
Report on Co-development Terms & Agreements in Pharma, Biotech and Diagnostics

Report on Co-development Terms & Agreements in Pharma, Biotech and Diagnostics

The Co-development Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies. [More]
Experimental drug shows promise as viable treatment for anemia of inflammation

Experimental drug shows promise as viable treatment for anemia of inflammation

An experimental drug designed to help regulate the blood's iron supply shows promise as a viable first treatment for anemia of inflammation, according to results from the first human study of the treatment published online today in Blood, the Journal of the American Society of Hematology. [More]
Researchers identify mutated forms of gene that encodes unregulated enzyme driving CML

Researchers identify mutated forms of gene that encodes unregulated enzyme driving CML

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have identified and characterized mutated forms of the gene that encodes BCR-ABL, the unregulated enzyme driving the blood cancer chronic myeloid leukemia (CML). [More]
Targeting club cells may help shorten duration of flu symptoms

Targeting club cells may help shorten duration of flu symptoms

A specialized subset of lung cells can shake flu infection, yet they remain stamped with an inflammatory gene signature that wreaks havoc in the lung, according to a study published in The Journal of Experimental Medicine. [More]
Combination of NASBA and real-time qPCR detects aspergillosis with 100% accuracy

Combination of NASBA and real-time qPCR detects aspergillosis with 100% accuracy

The fungal infection invasive aspergillosis (IA) can be life threatening, especially in patients whose immune systems are weakened by chemotherapy or immunosuppressive drugs. Despite the critical need for early detection, IA remains difficult to diagnose. [More]
Researchers gain rare insight into pregnancy-associated breast cancer

Researchers gain rare insight into pregnancy-associated breast cancer

During pregnancy, certain hormones trigger specialized mammary stem cells to create milk-producing cells essential to lactation. [More]
Feist-Weiller, Caris Life Sciences partner to offer breakthrough technology to cancer patients

Feist-Weiller, Caris Life Sciences partner to offer breakthrough technology to cancer patients

Doctors at the LSU Health Shreveport Feist-Weiller Cancer Center will now have access to innovative, precision-medicine technology that determines the unique biological characteristics of each individual patient's cancer tumor. [More]
CAP awards accreditation to The Children's Hospital of Philadelphia Pathology & Laboratory Medicine

CAP awards accreditation to The Children's Hospital of Philadelphia Pathology & Laboratory Medicine

The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to The Children's Hospital of Philadelphia Pathology & Laboratory Medicine, Philadelphia, Pennsylvania based on results of a recent on-site inspection as part of the CAP's Accreditation Programs. [More]
CRI researchers identify gene linked to several childhood cancers

CRI researchers identify gene linked to several childhood cancers

Researchers at the Children-s Medical Center Research Institute at UT Southwestern have identified a gene that contributes to the development of several childhood cancers, in a study conducted with mice designed to model the cancers. [More]
Bio-Techne revenue increases 16% to $92.5 million in fourth quarter 2014

Bio-Techne revenue increases 16% to $92.5 million in fourth quarter 2014

Techne Corporation, (d/b/a Bio-Techne) today reported its financial results for the fourth quarter and full year ended June 30, 2014. [More]
Jazz Pharmaceuticals offers $500 million aggregate principal amount of exchangeable senior notes

Jazz Pharmaceuticals offers $500 million aggregate principal amount of exchangeable senior notes

Jazz Pharmaceuticals plc today announced that Jazz Investments I Limited, its wholly-owned subsidiary, priced its previously announced offering of $500 million aggregate principal amount of exchangeable senior notes due 2021. [More]
3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey). [More]
Study sheds light on genetic alterations that may contribute to luminal B breast cancer

Study sheds light on genetic alterations that may contribute to luminal B breast cancer

Researchers from the Lester and Sue Smith Breast Center at Baylor College of Medicine have uncovered new information about the genetic alterations that may contribute to the development of a subtype breast cancer typically associated with more aggressive forms of the disease and higher recurrence rates. [More]
MD Anderson partners with HIAE to address cancer burden in Brazil

MD Anderson partners with HIAE to address cancer burden in Brazil

The University of Texas MD Anderson Cancer Center has announced a partnership with Hospital Israelita Albert Einstein to pioneer multidisciplinary patient care in Brazil and advance MD Anderson's mission to eliminate cancer globally. [More]

Patient navigation may lead to better breast cancer care in high risk and minority women

Patient navigation, or the linking of a newly diagnosed cancer patient with a professional trained in assisting patients though the complex journey of cancer diagnosis and treatment, may lead to better breast cancer care in high risk and minority women. [More]
Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS). [More]
Blood test can predict recurrence of HPV-linked oral cancers

Blood test can predict recurrence of HPV-linked oral cancers

Research published yesterday indicates that recurrence of human papillomavirus (HPV)-induced cancers affecting the oropharynx (the area of the throat just behind the mouth) can be predicted by blood and saliva tests that screen for DNA fragments from HPV that have been shed by cancer cells. [More]